Immune Regulation of Disseminated Cancer Cell Dormancy

播散性癌细胞休眠的免疫调节

基本信息

项目摘要

SUMMARY: Most cancer patients do not die from primary tumors but from the metastatic disease. Before formation of lethal metastases, disseminated cancer cells (DCCs) may stay dormant for up to decades, shown in clinics as the minimal residual disease (MRD), for which effective therapies are unavailable. Immunotherapies have made significant progress. However, most of the research focuses on primary tumors. Much less is known for the metastatic disease, in particular for MRD. The overarching goal of this proposal is to uncover mechanisms involved in the interaction between dormant DCCs and the immune system and therefore reveal therapeutic opportunities for MRD before the development into a full-blown lethal disease. We will determine the specific phenotypes of dormant DCCs and the associated immune cells relative to outgrowing metastases using single-cell RNA-sequencing, mass cytometry (or CyTOF), and Nanostring technologies. An important preclinical model that will be used throughout the study is the MMTV-ErbB2 mice, which develop spontaneous dormant DCCs in secondary organs. Compared to widely used models involving transplantation of established tumors or vaccination, this model will better mimic real-life situations in patients, as the immune system co- evolve with the cancer cells since their inception. In Aim 1, we will determine if T cells inhibit the expansion of DCCs via induction of dormancy and the mechanisms involved. We will test if T cell depletion allows the reactivation of dormant DCCs in the MMTV-ErbB2 model but also an orthotopic model as a complement. We will also test if immune cytokines induce DCC dormancy in 3D organoid cultures and in vivo and determine the cellular source of these cytokines. In Aim 2, we will determine if DCCs use the dormancy program to induce immune-suppression/-evasion via regulation of immune checkpoints. Specifically, we will test if dormancy- inducing cytokines and transcription factors regulate expression of immunoregulatory factors. immune-evasion genes to determine if the dormancy program in general is used by DCCs to avoid immune response and therefore persist. We will also test if immune checkpoint inhibitors enable immune reactions against dormant DCCs. Together, these approaches will allow us to understand if the immune system induces DCC dormancy, if the dormancy program enables evasion of suppression of the immune response, and if intervention of these processes will eliminate dormant DCCs. Thus, this study should reveal therapeutic opportunities to treat MRD and thereby minimize the disease recurrence that kills the majority of cancer patients.
摘要:大多数癌症患者不是死于原发肿瘤,而是死于转移性肿瘤。之前

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Julio A. Aguirre-Ghiso其他文献

Models, mechanisms and clinical evidence for cancer dormancy
癌症休眠的模型、机制和临床证据
  • DOI:
    10.1038/nrc2256
  • 发表时间:
    2007-11-01
  • 期刊:
  • 影响因子:
    66.800
  • 作者:
    Julio A. Aguirre-Ghiso
  • 通讯作者:
    Julio A. Aguirre-Ghiso
Targeting PERK Arm of Unfolded Protein Response Helps to Eliminate Therapy-Induced Residual Senescent-like Acute Myeloid Leukemia Cells
  • DOI:
    10.1182/blood-2024-203451
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Gowri Poigaialwar;Sumiko Takao;Sovira Chaudhry;Laura K. Schmalbrock;Varun Gupta;Alex Kentsis;Julio A. Aguirre-Ghiso;Marina Konopleva;Maria S. Sosa;Anna Skwarska
  • 通讯作者:
    Anna Skwarska

Julio A. Aguirre-Ghiso的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Julio A. Aguirre-Ghiso', 18)}}的其他基金

Epigenetic and microenvironmental regulation of dormant disseminated cancer
休眠播散性癌症的表观遗传学和微环境调控
  • 批准号:
    10525056
  • 财政年份:
    2022
  • 资助金额:
    $ 8.47万
  • 项目类别:
Functional Determinants of Metastatic Dormancy
转移休眠的功能决定因素
  • 批准号:
    10428636
  • 财政年份:
    2022
  • 资助金额:
    $ 8.47万
  • 项目类别:
Functional Determinants of Metastatic Dormancy
转移休眠的功能决定因素
  • 批准号:
    10516864
  • 财政年份:
    2022
  • 资助金额:
    $ 8.47万
  • 项目类别:
Functional Determinants of Metastatic Dormancy
转移休眠的功能决定因素
  • 批准号:
    10678829
  • 财政年份:
    2022
  • 资助金额:
    $ 8.47万
  • 项目类别:
Immune Regulation of Disseminated Cancer Cell Dormancy
播散性癌细胞休眠的免疫调节
  • 批准号:
    10513907
  • 财政年份:
    2021
  • 资助金额:
    $ 8.47万
  • 项目类别:
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance
葡萄膜黑色素瘤休眠机制及靶向治疗耐受性
  • 批准号:
    10645058
  • 财政年份:
    2020
  • 资助金额:
    $ 8.47万
  • 项目类别:
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance
葡萄膜黑色素瘤休眠机制及靶向治疗耐受性
  • 批准号:
    10226338
  • 财政年份:
    2020
  • 资助金额:
    $ 8.47万
  • 项目类别:
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance
葡萄膜黑色素瘤休眠机制及靶向治疗耐受性
  • 批准号:
    10414811
  • 财政年份:
    2020
  • 资助金额:
    $ 8.47万
  • 项目类别:
Epigenetic and microenvironmental regulation of dormant disseminated cancer
休眠播散性癌症的表观遗传学和微环境调控
  • 批准号:
    9924485
  • 财政年份:
    2017
  • 资助金额:
    $ 8.47万
  • 项目类别:
Epigenetic and microenvironmental regulation of dormant disseminated cancer
休眠播散性癌症的表观遗传学和微环境调控
  • 批准号:
    9502259
  • 财政年份:
    2017
  • 资助金额:
    $ 8.47万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 8.47万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.47万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 8.47万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.47万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 8.47万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.47万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 8.47万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 8.47万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 8.47万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.47万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了